Human Anatomy and Physiology I (BIO 0310I) lecture

Human Anatomy and Physiology II (BIO 0310II) lecture and laboratory

Biology Survey I (BIO 0151) lecture

Biology Survey II (BIO 0153) lecture

Theses:

GPR30 Mediates Rapid, Non-Genomic 17b-Estradiol Signaling in Primary Cultured Human Fibroblasts via Ga_i2 and Src Mediated Transactivation of the Epidermal Growth Factor Receptor.  Moreland, Kirby Trent, (2009).

Purification and Functional Analysis of Recombinant VirG from Shigella flexneri  Moreland, Kirby Trent, (1997).

Journal Articles:

Dual Role of Recombinant Otolin-1 as a Matrix Protein and a Modulator of Calcite Crystal Morphology .  Moreland, K. Trent, et. al. Manuscript in preparation (2012).

COX-1 and COX-2 Participate in 5,6-Epoxyeicosatrienoic acid-Induced Contraction of Rabbit Intralobar Pulmonary Arteries.  Moreland, K.T. et al. JPET 321:446–454 (2007).

A Three Step Mechanism for Selective Inhibition of Cyclo-Oxygenase-2 by Diarylheterocyclic Inhibitors.  Walker, M. C., et. al. Biochemical Journal 357, 709-718 (2001).

Structural Insights into the Stereochemistry of the Cyclooxygenase Reaction.  Kiefer, J.R., et al. Nature 405, 97-101 (2000).

Crystallization of Recombinant Cyclo-oxygenase-2.  Stevens, A.M., et al. Journal of Crystal Growth 196, 350-355 (1999).

Proceedings:

Mechanism of Inhibition of Novel COX-2 Inhibitors.  Gierse, et al. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 5, Chapter 56, Kluwer Academic/Plenum Publishers (2002).

Selective Inhibition of Cyclooxygenase-1 Inhibits 5,6-EET-Induced Contraction of Rabbit Intralobar Pulmonary Arteries.  K. Trent Moreland, et al.; Saint Louis University 10th Annual Graduate Research Symposium March 26, 2004.

Molecular Basis for the Exquisite COX-2 Specificity of Valdecoxib, a Second-Generation COX-2 Inhibitor.  Ravi G. Kurumbail, et al.; presented at the Eicosanoids and other Bioactive Lipids in Cancer, Nashville, TN  October 14, 2001.

Crystallization Screens and Limited Proteolysis to Generate Diffraction Quality Crystals.  Jennifer L. Pawlitz, et al.; Anna’s talk at Recent Approaches in Macromolecular Crystallization in San Diego.

Molecular Basis of Selectivity and Potency of COX-2 Inhibitors.  J. Gierse, et al.; presented at the 11th International Conference on Advances in Prostaglandin and Leukotriene Research, Florence, Italy, June 4-8, 2000.

Molecular Basis for the Binding and Selectivity of a New COX-2 Inhibitor: Valdecoxib.  William Stallings, et al.; presented at the 2000 American Crystallographic Association meeting in Minnesota.

Snapshot of the Cyclooxygenase Reaction Pathway: Structure of Prostaglandin at the Active Site of COX-2.  J. Kiefer, et al.; presented at the 6th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Boston, Massacheusetts, Sept. 12-15, 1999.

A General Mechanism for Selective Inhibition of Cyclooxygenase-1 and -2 as Probed by a Series of Diaryl Heterocycles.  M. C. Walker, et al.;  presented at the American Society of Biochemistry and Molecular Biology Meeting, San Francisco, California, May 16-20, 1999.

Purification and Properties of a Recombinant Form of Vir G from Shigella flexneri.  Kirby Trent Moreland, et al.; Saint Louis University 3rd Annual Graduate Research Symposium 1996.

Postdoctoral Research Associate

Biosafety Fellow

Certificate in University Teaching Skills

December 2008

Saint Louis University, St. Louis, MO

Washington University School of Medicine Developmental Cardiology and Pulmonary T32 training grant (NIH 5 T32 HL07873), 2009-2011